Description
Anti-Coagulation Factor XI Antibody, Non-Fucosylated (BioBet-848ZP) is a human monoclonal IgG antibody against Coagulation Factor XI. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Thromboembolism
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Coagulation Factor XI antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
F11
Full Name
coagulation factor XI
Background
This gene encodes coagulation factor XI of the blood coagulation cascade. This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. During activation of the plasma factor XI, an internal peptide bond is cleaved by factor XIIa (or XII) in each of the two chains, resulting in activated factor XIa, a serine protease composed of two heavy and two light chains held together by disulfide bonds. This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality.
Alternative Names
F11; coagulation factor XI; FXI; PTA; plasma thromboplastin antecedent
Gene ID
2160
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with F11 include Factor Xi Deficiency and Hemorrhagic Disease.
Related Pathways
Its related pathways are Formation of Fibrin Clot (Clotting Cascade) and Response to elevated platelet cytosolic Ca2+.
Function
Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
Field of research
Gene Regulation antibody
Post-translational modifications
Autophosphorylated on Ser-2056, Thr-2609, Thr-2638 and Thr-2647. Ser-2056 and Thr-2609 are DNA damage-inducible phosphorylation sites (inducible with ionizing radiation, IR) dephosphorylated by PPP5C. Autophosphorylation induces a conformational change that leads to remodeling of the DNA-PK complex, requisite for efficient end processing and DNA repair. S-nitrosylated by GAPDH. Polyubiquitinated by RNF144A, leading to proteasomal degradation.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-848ZP
Description
The antibody capable of binding to the coagulation Factor XI can be used as agents inhibiting platelet aggregation and by this inhibits thrombus formation
Antibody Indication
Thromboembolism
